Healthcare
Pacific Edge Limited(PFGTF)
Live Price
Offline$0.171
+0.00% today
1Y Change
+174.41%
Window
Jun 23, 2025 โ Jun 19, 2026
- Market Cap
- $140.00M
- Revenue Growth
- -16.2%
- EPS Growth
- -1.6%
- Dividend Yield
- 0.0%
Coverage: 257 bars ยท Jun 23, 2025 โ Jun 19, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Pacific Edge Limited (PFGTF) is a Healthcare stock with a market cap of $140.00M and listed on OTC. The stock last traded around $0.17 and up 174.4% across the available one-year price window (Jun 23, 2025 โ Jun 19, 2026). Baseline metrics include revenue growth of -16.2%, EPS growth of -1.6%, a dividend yield of 0.0%. What stands out right now is revenue -16.2%, EPS -1.6%, free cash flow +4.1% with operating margin -221.8% and ROIC -122.8%. Valuation already assumes a fairly strong business story at price/sales 8.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PFGTF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-16.2% vs +7.6% peer median
Operating Margin
Below sector median
-221.8% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 27, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -16.2% and EPS is at -1.6%, with operating margin around -221.8%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -5.7% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 27, 2026 | โ | +0.0% | -17.2% | โ |
2025 Nov 23, 2025 | โ | +0.0% | +0.0% | +0.0% |
2025 May 29, 2025 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PFGTF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PFGTF Max Drawdown
-70.65%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PFGTF and SPY.
Company Overview
Pacific Edge Limited
Other OTC
Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, Australia, and Singapore. It operates in two segments, Commercial and Research. The company offers Cxbladder, a genomic urine tests for the detection and management of bladder cancer. It is also developing Cxbladder Resolve, a product that identifies those patients who are likely to have aggressive or more advanced bladder cancer; Cxbladder Triage, a product that identifies patients with haematuria who have a low probability of bladder cancer; Cxbladder Detect that enables the non-invasive detection of bladder and other urinary tract cancers; and Cxbladder Monitor, which allows urologists to monitor bladder cancer patients for recurrence of the disease. In addition, the company is developing Cxcolorectal, a prognostic gene signature for patients diagnosed with stage II or stage III colorectal cancers; and products for bladder, gastric, colorectal, endometrial cancers, and melanoma. Pacific Edge Limited was incorporated in 2001 and is headquartered in Dunedin, New Zealand.
- Leadership
- Peter Meintjes
- IPO Date
- Nov 2, 2016
- Employees
- 114
- Street Address
- Centre for Innovation
- Mailing
- Dunedin, 9016
- Region
- Dunedin, NZ
- Reporting Currency
- USD
- Investor Line
- 64 3 479 5800
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 8.3
- Price/Book
- 5.5
Growth
- Revenue
- -16.2%
- EPS
- -1.6%
- Free Cash Flow
- +4.1%
Profitability
- Gross Margin
- 26.2%
- Operating Margin
- -221.8%
- Net Margin
- -205.3%
- ROE
- -130.4%
- ROIC
- -122.8%
Balance Sheet
- Debt/Equity
- 0.09
- Current Ratio
- 4.10
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.